Figure 1.

Correlative immune factors of response to teclistamab monotherapy in the MajesTEC-1 study in the periphery at baseline. (A) Diagram of patients, samples, and analysis from the MajesTEC-1 study. (B) Frequency of T cells by response assessed by flow cytometry in the periphery at the RP2D dose, with representative staining shown on the right of the panel. (C) Absolute CD3 T-cell counts by flow cytometry relative to response. (D) Absolute CD8 T-cell counts assessed by flow cytometry (TBNK kit). (E) Percentage of Tregs from CD4 T cells at baseline relative to response at the RP2D dose, with representative staining shown on the right of the panel. (F) Frequency of CD38-expressing Tregs at baseline assessed by flow cytometry and relative to response, with representative staining shown on the right of the panel. (G) Frequency of naive CD8 T cells from the parent population of CD45⁺ T cells assessed in a subset of patients from the active dose cohorts assessed by CyTOF, with representative staining shown on the right of the panel. Statistical significance was evaluated using the Wilcoxon rank-sum test. CM, central memory; EM, effector memory; TBNK, T cells, B cells, and natural killer cells; TEMRA, terminally differentiated effector memory cells re-expressing CD45RA.